Tevogen Signs Letter Of Intent To Acquire CRO

Tevogen Bio Holdings announced on Feb. 27, 2026 that it signed a non-exclusive, non-binding letter of intent to evaluate a potential transaction with a global contract research organization (CRO). The proposed deal could expand Tevogen’s clinical development capabilities and introduce revenue-generating services, but remains subject to due diligence, definitive agreements, regulatory approvals, and customary closing conditions.